Date for Share Split in Q-Med Determined.STOCKHOLM, Sweden -- A 4:1 share split was adopted at Q-Med's (STO:QMED) Annual General Meeting on May 3, 2006. This means that one former share is replaced by four new shares. The record day will be Wednesday June 14 and the new shares will be registered in shareholders' accounts on Thursday June 15. The last day for shares to be traded before the split will be Friday June 9, 2006. The first day for shares to be traded after the split will be Monday June 12, 2006. The split means that the number of outstanding shares will increase from 24,816,243 to 99,265,372 shares. After the split, a round lot in Q-Med, which today consists of 50 shares, will be changed to 100 shares. In the US, Q-Med AB's affiliate is the wholly-owned subsidiary Q-Med Scandinavia, Inc. Q-Med is a rapidly growing and profitable biotechnology/medical device company that develops, produces, markets and sells medical implants. All products are based on the company's patented technology for the production of stabilized non-animal hyaluronic acid hyaluronic acid: see mucopolysaccharide. Hyaluronic acid A polysaccharide which is an integral part of the gel-like substance of animal connective tissue; it supposedly serves as a lubricant and shock absorbent in the joints. , NASHA NASHA Non-Animal, Stabilized Hyaluronic Acid (trademark of Q-Med AB; Uppsala, Sweden) NASHA National Association for Speech and Hearing Action (Rockville, MD) (TM). The products covered by the RESTYLANE trademark are used for the filling out of lips and facial wrinkles and for facial contouring and today account for the majority of sales. DUROLANE is Q-Med's product for the treatment of osteoarthritis osteoarthritis or osteoarthrosis or degenerative joint disease Most common joint disorder, afflicting over 80% of those who reach age 70. It does not involve excessive inflammation and may have no symptoms, especially at first. of the hip and knee joints. DEFLUX is a product for the treatment of vesicoureteral reflux Vesicoureteral Reflux Definition Vesicoureteral reflux (VUR) refers to a condition in which urine flows from the bladder, back up the ureter, and back into the kidneys. (a malformation malformation /mal·for·ma·tion/ (-for-ma´shun) 1. a type of anomaly. 2. a morphologic defect of an organ or larger region of the body, resulting from an intrinsically abnormal developmental process. of the urinary bladder) in children. ZUIDEX is used for the treatment of stress urinary incontinence stress urinary incontinence n. See stress incontinence. in women. Q-Med today has approximately 560 employees, with approximately 370 at the company's head office and production facility in Uppsala. The Q-Med share is listed on the O-list of the Stockholm Stock Exchange The Stockholm Stock Exchange (Swedish: Stockholmsbörsen) is a stock exchange located in Stockholm, Sweden. Founded in 1863 [1] it is the primary securities exchange of the Nordic Countries. . Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Tel: +46(0)18-474 90 00, Fax: +46(0)18-474 90 01 info@q-med.com, www.q-med.com, Corporate identity number 556258-6882. This information was brought to you by Waymaker http://www.waymaker.net |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion